Summary Graybug Vision Inc (Graybug Vision) is a clinical stage pharmaceutical company that develops next generation products for the treatment of chronic vision-threatening diseases of the retina and optic nerve.The company’s lead candidate include GB-102, a clinical-stage depot formulation of sunitinib malatcontains, which is a single small molecule compound that blocks multiple pathogenic angiogenesis pathways included in choroidal neovascularization that causes neovascular or wet age-related macular degeneration.
Its pipeline portfolio offers candidates for the treatment of major eye diseases such as glaucoma, retinal vein occlusion, diabetic macular edema, corneal graft rejection, and others.Graybug Vision’s proprietary ocular drug delivery technologies enable the delivery of the compounds to the various compartments of the eye.
The company operates through its research center located in Baltimore, Maryland, the US. Graybug Vision is headquartered in Redwood City, California, the US.
Graybug Vision Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
The ePRO, ePatient Diaries, and eCOA market in Middle East and Africa is expected to grow from US$ 48.4 million in 2021 to US$ 112.3 million by 2028; it is estimated to grow at a CAGR of 12.8% from 2021 to 2028. Increasing number of smartphone users is likely to boost the ePRO, e-Patient Diaries, and eCOA’s adoption in the coming years. Mobile-enabled...
The ePRO, ePatient Diaries, and eCOA market in South and Central America is expected to grow from US$ 90.3 million in 2021 to US$ 229.0 million by 2028; it is estimated to grow at a CAGR of 14.2% from 2021 to 2028. Patient centricity means designing a treatment, clinical trial, or other health solution centered around the patient. Creating...
The Global Biosimilars Partnering Terms and Agreements 2010 to 2021 report provides an understanding and access to the Biosimilars partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in Biosimilars partnering deals Disclosed headlines, upfronts, milestones and royalties...
Global Optical Genome Mapping Market, By Component (Instruments v/s Consumables), By Application (Genome Assembly, SV Detection, Microbial Strain Typing, Haplotype Phasing, Others), By End User (Biotechnology & Pharmaceutical Companies, Research & Academic Institutions, Clinical Laboratories, Others), By Region, Competition Forecast...
175 pages •
By The Business Research Company
• Aug 2021
Major players in the aseptic packaging market are Reynolds Group Holdings Limited, Amcor Limited, Tetra Laval International S.A, Greatview Aseptic Packaging Co. Ltd., Tetra Pak International SA, Sig Combibloc AG, SIG Combiboc Obeikan, ELOPAK Group, Sealed Air Corporation, DS Smith Plc, and UFlex Limited. The global aseptic packaging...
The global n-hexane market reached a volume of 2.8 Million Tons in 2020. Looking forward, the analyst expects the market to exhibit stable growth during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use industries....
Free Fatty Acid Receptor 1 - Drugs In Development, 2021 Summary According to the recently published report ’Free Fatty Acid Receptor 1 - Drugs In Development, 2021’; Free Fatty Acid Receptor 1 (G Protein Coupled Receptor 40 or GPR40 or FFAR1) pipeline Target constitutes close to 18 molecules. Out...
Gastric Inhibitory Polypeptide Receptor - Drugs In Development, 2021 Summary Gastric Inhibitory Polypeptide Receptor (Glucose Dependent Insulinotropic Polypeptide Receptor or GIPR) pipeline Target constitutes close to 26 molecules. Out of which approximately 23 molecules are developed by companies...
At present, the pharmaceutical industry is dominated by the presence of small molecule products, which represent close to 80% of the overall pipeline. Even though biologics have shown significant promise in the treatment of a wide range of disorders, in recent years, approval of novel small molecules has been...
Number Of Enterprises
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.